ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving White Blood Cell Collection From Healthy Donors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01553214
Recruitment Status : Recruiting
First Posted : March 14, 2012
Last Update Posted : August 9, 2018
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)

March 10, 2012
March 14, 2012
August 9, 2018
March 7, 2012
January 1, 2030   (Final data collection date for primary outcome measure)
To determine the operational feasibility and impact of managing a volunteer community donor granulocytapheresis program [ Time Frame: Annually. The feasibility of continuing the granulocyte donation program will be assessed, based on resource need and allocation, operational impact, adverse effects in donors, and survival outcomes of recipients. ]
To determine the operational feasibility and impact of managing a volunteer community donor granulocytapheresis program
Complete list of historical versions of study NCT01553214 on ClinicalTrials.gov Archive Site
To monitor the frequency and severity (symptom grade) of acute adverse effects due to a single dose of filgrastim and dexamethasone in volunteer donors [ Time Frame: 48 hours after last GCSF dose. The feasibility of continuing the granulocyte donation program will be assessed, based on resource need and allocation, operational impact, adverse effects in donors, and survival outcomes of recipients. ]
To monitor the frequency and severity (symptom grade) of acute adverse effects due to a single dose of filgrastim and dexamethasone in volunteer donors
Not Provided
Not Provided
 
Improving White Blood Cell Collection From Healthy Donors
Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone

Background:

- White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells. Transfusions of these cells can help improve the body's ability to fight infection. However, most of the cells are located in the bone marrow or spleen, and are hard to collect from healthy donors. Two drugs, filgrastim and dexamethasone, can help move the cells to the bloodstream to be collected by apheresis. Researchers want to study the best ways to collect these white blood cells. They also want to monitor the effects of the injections and donations on the volunteer donors.

Objectives:

- To improve the amount and quality of granulocytes (white blood cells) collected by apheresis for donation.

Eligibility:

- Healthy volunteers between 18 and 75 years of age.

Design:

  • Participants will be screened with a physical exam and medical history. Initial blood tests will be done to check for eligibility.
  • Participants will donate granulocytes by apheresis a maximum of 12 times in 1 year. Donations will not usually be requested more often than every 4 weeks. Donors will be allowed to decline participation at any time.
  • Participants will have one injection of filgrastim 12 to 24 hours before donation. They will also have two tablets of dexamethasone 12 hours before donation.
  • White blood cells will be collected through apheresis. The apheresis will last about 2 hours.
  • Participants will be eligible to donate until they reach their 76th birthday.
Bacterial and fungal infections in neutropenic patients or in patients with inherited disorders of neutrophil function continue to cause substantial morbidity and mortality. In particular, fungal infections are an increasingly important cause of death in patients receiving aggressive chemotherapy, in patients undergoing hematopoietic stem cell transplantation (HSCT), in patients with chronic granulomatous disease, and in patients with bone marrow failure syndromes such as severe aplastic anemia. The strongest predictor of progression and death from invasive mold infection in the cancer/ HSCT setting is the duration of neutropenia. Any modality which increases the granulocyte count during periods of profound neutropenia and severe infection is thus likely to be of clinical benefit. In the 1970-80 s, collection of granulocyte concentrates by apheresis of healthy donors stimulated with corticosteroids alone yielded products with an insufficient number of granulocytes to substantially raise the circulating counts in neutropenic patients. Transfusion of such components was variably associated with clinical benefit. More recently, the ability to give donors recombinant human granulocyte colony-stimulating factor (G-CSF) in combination with corticosteroids (dexamethasone) dramatically increases the circulating neutrophil count prior to apheresis and results in the collection of granulocyte concentrates containing 2 to 6 times as many cells as those collected using steroids alone. Transfusion of granulocyte concentrates collected after G-CSF and dexamethasone stimulation of the donor typically increases the recipient s granulocyte count by 1,000 cells/uL, and the increase in counts is generally sustained for 24 to 48 hours. Transfusion of daily or every other day granulocytes derived by apheresis of G-CSF and dexamethasone-stimulated donors has been associated in observational and retrospective studies with clearance of life-threatening infections in neutropenic patients, but a single small randomized prospective study did not demonstrate improved survival in neutropenic infected patients who received granulocytes. Granulocyte components are not recognized as a licensed blood component by the Food and Drug Administration (FDA), and neither G-CSF nor dexamethasone is approved by the FDA for use in allogeneic granulocytapheresis donors. Studies at the NIH Department of Transfusion Medicine (DTM) have defined the optimal timing and dose of these drugs in granulocyte donors, and these components have been used for clinical care since 1996. Short term adverse effects of G-CSF and dexamethasone, including bone pain, myalgias, headache, insomnia and fatigue, are well known and possible long term effects, including cataracts from serial steroid administration, have been described. The purpose of the current protocol is to determine the operational feasibility of managing a volunteer community donor granulocytapheresis program and to provide informed consent for the administration of filgrastim and dexamethasone to volunteer donors donating granulocytes by apheresis. Donor accrual and retention, immediate short term adverse effects of G-CSF and dexamethasone, and any long term effects, will be assessed in healthy subjects who will be permitted to donate granulocytes a maximum of 12 times per year. Participants will be selected based on general blood donor eligibility criteria, adequacy of antecubital venous access, and interest in the program. Most subjects will already have experience as plateletpheresis donors. The toxicity of granulocyte transfusions and the survival and discharge rates of the transfusion recipients will be monitored, but the protocol is not designed to evaluate the efficacy of granulocyte transfusions.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
  • Blood Donor
  • Leukocyte Transfusion
  • Granulocyte Colony-Stimulation Factor
  • Blood Component Removal
  • Drug: Filgrastim (G-CSF)
    Recombinant G-CSF is available from the Clinical Center pharmacy in colorless glass, single-use vials containing 480 mcg G-CSF in 1.6 mL vials (300 mcg/mL). It is formulated as a sterile, clear, colorless liquid in 10 mm sodium acetate buffer at pH 4.0. The quantitative composition (per mL) is: Recombinant human G-CSF 300 mcg Acetate 0.59 mg Mannitol 50 mg Tween 80TM 0.004% Sodium 0.035 mg Water for injection (qs ad) to 1.0 mL Storage: The intact vials of G-CSF should be stored under refrigeration (2-8 degrees Celsius). Administration: G-CSF is administered subcutaneously, with the entire contents of one 1.6 mL vial given in one injection 12 to 24 hours prior to apheresis.Stability: G-CSF in the intact vial is stable for 36 months when stored in a refrigerator at 2-8 degrees Celsius. A single brief exposure (up to 7 days) to elevated temperatures (<37 degrees Celsius) does not affect the stability. G-CSF should not be frozen, and vials that have been frozen should not be used.
  • Drug: Dexamethasone
    Oral dexamethasone is available from the Clinical Center pharmacy as green 4 mg tablets. The tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, starch, sucrose, FD&amp;C Green No. 3, FD&amp;C Yellow No. 10, and FD&amp;C Yellow No. 6. They are packaged in unit-dose blister pack strips. Storage: Dexamethasone tablets should be stored at room temperature (20-25 degrees Celsius). Administration: Dexamethasone is administered as two 4-mg tablets 12 hours prior to apheresis (approximately one hour after dinner the evening prior to apheresis). Stability: Dexamethasone is stable for 36 months when stored at room temperature in an unopened blister pack.
  • 1
    There are no arms in this study
    Interventions:
    • Drug: Filgrastim (G-CSF)
    • Drug: Dexamethasone
  • 2
    There are no arms in this study
    Interventions:
    • Drug: Filgrastim (G-CSF)
    • Drug: Dexamethasone
  • 3
    There are no arms in this study
    Intervention: Drug: Filgrastim (G-CSF)
  • 4
    There are no arms in this study
    Intervention: Drug: Filgrastim (G-CSF)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
Same as current
January 1, 2030
January 1, 2030   (Final data collection date for primary outcome measure)
  • INCLUSION CRITERIA:
  • Donors shall meet all donor eligibility criteria for allogeneic blood donors, as defined in the most recent editions of the AABB Standards and FDA Code of Federal Regulations (21CFR640). In addition, donors shall meet the following restrictions:
  • Age greater than or equal to18 and less than or equal to 75 years
  • If hypertension is present, must be well-controlled on medications
  • If peptic ulcer disease has been diagnosed in the past, symptoms must be well-controlled on medications
  • If cataracts have been diagnosed in the past, records from subject s ophthalmologist must be obtained indicating type of cataract. If PSC was diagnosed in the past, subject may receive G-CSF but not dexamethasone. The only exception to this is a history of bilateral cataract extractions due to PSC.

EXCLUSION CRITERIA:

  • Information obtained from health history screen that does not meet the allogeneic donor eligibility criteria of the AABB Standards or the FDA CFR.
  • Weight less than 50 kg (110 lbs)
  • History of coronary heart disease
  • Uncontrolled hypertension (systolic BP >160, diastolic BP >100)
  • History of hepatitis or injection drug use
  • Diabetes mellitus requiring insulin
  • Active, symptomatic peptic ulcer disease
  • History of iritis or episcleritis
  • Sickle cell disease (sickle trait is acceptable). Testing for hemoglobin S is not required.
  • Lithium therapy
  • Pregnancy or nursing (breast feeding)
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Yes
Contact: Yu Ying Yau, R.N. (301) 435-3049 yyau@mail.cc.nih.gov
Contact: Kathleen A Cantilena, M.D. (301) 451-8637 ccantilena@mail.nih.gov
United States
 
 
NCT01553214
120096
12-CC-0096
Not Provided
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC)
Not Provided
Principal Investigator: Kathleen A Cantilena, M.D. National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
May 30, 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP